Log In
BCIQ
Print this Print this
 

fostemsavir (BMS-663068)

  Manage Alerts
Collapse Summary General Information
Company ViiV Healthcare Ltd.
DescriptionHIV-1 attachment inhibitor that binds directly to HIV-1 gp120
Molecular Target HIV gp120
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationHIV / AIDS
Indication DetailsTreat HIV-1 infection; Treat HIV-1 infection in combination with other antiretroviral agents in heavily treatment-experienced adults
Regulatory Designation U.S. - Breakthrough Therapy (Treat HIV-1 infection in combination with other antiretroviral agents in heavily treatment-experienced adults)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

$1,268.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/18/2015

Undisclosed

Undisclosed

$1,268.0M

Get a free BioCentury trial today